Cadent Therapeutics, Inc.

Pfizer Corporation

Novartis Ag

Luc Therapeutics, Inc.

Frank S Menniti

Robert A Volkmann

David R Anderson

Christopher Fanger

Bertrand Leo Chenard

Mario D Saltarelli

Yuelian Xu

Mark Allen Sanner

Patricia A Seymour

Michael K Ahlijanian

Chris John Helal

Lit-Fui Lau

Christoper B Cooper

Willard M Welch, Jr

Anabella Villalobos

Annabella Villalobos

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

NMDA receptor modulators and uses thereof

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

Heteroaromatic NMDA receptor modulators and uses thereof

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.

Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B

The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R, R, L, L, X, Y, and Y' are described therein.

N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B

Thienopyrimidinone NMDA receptor modulators and uses thereof

Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

The present invention relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I where R1, R2, L1, L2, X, Y, and Y' are described therein. In an aspect, compounds of formula I are described and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or stereoisomers thereof wherein: L1 is straight or branched C1-C5 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, ORIO, NH2, NHRio, and N(Rlo)(Rio&#x2032;) provided that no more than one oxygen or nitrogen is attached to any carbon. 

N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B

Growing community of inventors

Mystic, CT, United States of America

Frank S Menniti